An influx of biosimilars may be coming to the Medicare Part D market in 2023 as multiple manufacturers launch biosimilars of Humira. This white paper explores the dynamics affecting biosimilars in Medicare Part D and key stakeholder considerations under the current and proposed Part D benefit design for 2024.

This report was commissioned by the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center.